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Background: The mechanism by which normal body mass index (BMI) with central
adiposity (NWCA) increases the risk of the diseases has not been completely elucidated.
The inflammatory role of immunoglobulin G (IgG) N-glycosylation in obesity defined by
BMI or central adiposity defined by waist-to-hip ratio (WHR) was reported, respectively. We
undertook this three-center cross-sectional study to determine the association between the
IgG N-glycans and NWCA.
Methods: The participants were categorized into four different phenotypes: normal BMI
with normal WHR (NW), normal BMI with central adiposity (NWCA), obesity with normal
WHR (ONCA) and obesity with central adiposity (OCA). The IgG N-glycans were analyzed
using ultra-performance liquid chromatography analysis of released glycans, and differences
among groups were compared.
Results: In total, 17 out of 24 initial IgG N-glycans were significantly different among the
four groups (NW, ONCA, NWCA and OCA) (P<0.05/6*78=0.0001). The changes of IgG
glycans in central obesity (12 GPs) were more than those in obesity (3 GPs). In addition,
lower galactosylation and bisecting GlcNAc and higher fucosylation were associated with
increased risk of NWCA.
Conclusion: Central obesity was involved in more changes of IgG N-glycosylation repre-
senting stronger inflammation than obesity, which might make a greater contribution to the
risk of related disorders. NWCA was associated with an increased pro-inflammatory of IgG
N-glycosylation, which was accompanied by the development of central obesity and other
related disorders.
Keywords: body mass index, BMI, waist-to-hip ratio, WHR, normal BMI with central
adiposity, immunoglobulin G, N-glycosylation, N-glycan
Introduction
Obesity, especially central adiposity, is a growing public health problem.1,2 Obesity
defined by body mass index (BMI) or central adiposity such as measuring by waist
circumference and waist-to-hip ratio (WHR) is one of themost important risk factors of
the majority of chronic non-communicable diseases, including metabolic syndrome,
cardiovascular disease and cancers.3,4 In addition, a multicohort study has shown that
overweight participants lost 1 disease-free year, the mild obesity 3 to 4 years and the
severe obesity 7 to 8 years compared with normal BMI participants.5
However, the BMI does not consider body fat distribution, which is an important
limitation since there are suggestions that the metabolic complications of central
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adiposity are more closely related to visceral adiposity than
overall adiposity.6 WHR is a good parameter of abdominal
fat accumulation, reflecting central adiposity more than
BMI.7–9 The increasing evidences show that central adiposity
makes a greater contribution to the risk of suffering insulin
resistance, type 2 diabetes, metabolic syndrome and cardio-
vascular diseases than general obesity.8–11 In addition, a
recent study showed that normal BMI with central adiposity
(NWCA), which is defined as normal BMI but abdominal fat
accumulation, is also associated with increased mortality risk
of total and cardiovascular disease.8 However, the mechan-
ism by which NWCA increases the risk of these diseases has
not been completely elucidated.
N-glycosylation, as the most common and essential
post-translational modification of human proteins, is closer
to biological function.12 N-glycosylation significantly
affects protein structure and function, and thus participates
in multiple physiology and pathologic process.12 Changes
in immunoglobulin G (IgG) N-glycosylation patterns have
been associated with the incidence and development of
aging, chronic non-communicable diseases and inflamma-
tory diseases.13,14 IgG plays an important role in the
human immune system, and N-glycans attach to the con-
served asparagine 297 in the fragment crystallizable (Fc)
part of this molecule and act as a switch between pro- and
anti-inflammatory IgG functionality, and even slight aber-
rant IgG N-glycosylation can promote inflammation.15
Obesity and central adiposity are characterized by a pro-
inflammatory state and elevated levels of inflammatory mar-
kers, such as C-reactive protein and interleukin-6, that have
been associated with risk of developing obesity and central
obesity.16,17 The inflammatory role of IgGN-glycosylation in
obesity defined by BMI and central adiposity defined by
WHR were, respectively, reported in European and
Australian populations.18,19 However, IgG N-glycosylation
patterns in NWCA remain unknown. We hypothesized that
the changes in IgG N-glycan profiles are involved in the
pathogenesis of NWCA by regulating the inflammatory
response. In the present study, we aimed to determine the
association between the IgG N-glycans and NWCA in the
multi-center cross-sectional study, and to further investigate
the potential role of IgG N-glycosylation in NWCA.
Materials And Methods
Ethical Approval
Written informed consent was obtained from each subject
at the beginning of the study, and the study has been
approved by the Ethics Committee of the Capital
Medical University, Beijing, China. The ethics approval
was given in compliance with the Declaration of Helsinki.
Participants
All participants were recruited from our three cohort stu-
dies, including Xicheng community-based cohort in the
Xuanwu hospital (from September 2009 to September
2012 of the baseline population), China suboptimal health
cohort study in the Jidong Oil-field hospital (from
September 2013 to September 2014 of the baseline popu-
lation) and Beijing health management cohort in the
Beijing Xiaotangshan hospital (from August 2014 to
October 2015 of the follow-up population).20–22 The inclu-
sion and exclusion criteria of the study population were as
follows: inclusion criteria: (1) signed informed consent
prior to participation, (2) age equal to or greater than 18
years and (3) no medication history during the previous 2
weeks; exclusion criteria: (1) underweight participants, (2)
pregnant or lactating women, (3) history of mental illness
or infectious disease and (4) history of stroke or other
cerebrovascular diseases, congenital heart disease, liver
disease, renal failure, malignant tumor, chronic obstructive
pulmonary disease, rheumatoid arthritis or other diseases.
Of note, the participants in the previous study who were
recruited from the Tiantan Hospital were eliminated
because they were diagnosed with ischemic stroke.22 The
flowchart for the process of including study population is
illustrated in Figure 1.
Diagnosis Of Obesity And Central
Adiposity
The body mass index (BMI) was calculated by the formula
weight (in kilograms)/height2 (in meters squared), which
was categorized as normal weight (BMI of 18.50 to 23.99
kg/m2), overweight (BMI of 24.00 to 27.99 kg/m2) and
obesity (BMI≥28.00 kg/m2).23 Underweight participants
(BMI<18.50 kg/m2) were excluded to avoid reverse causa-
tion. The waist-to-hip ratio (WHR) was calculated as waist
circumference (in centimeter)/height (in centimeter).
Central adiposity was defined using WHR of 0.85 or
higher in women and 0.90 or higher in men.24 The parti-
cipants were divided into four different obesity and central
adiposity groups for normal BMI with normal WHR
(NW), normal BMI with central adiposity (NWCA), obe-
sity with normal WHR (ONCA) and obesity with central
adiposity (OCA).
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Covariates
Each participant was required to complete a thorough
health examination, which included anthropometric mea-
surements and an analysis of the physical and chemical
properties of a blood sample. Blood samples were col-
lected from participants in the morning and plasma sam-
ples were separated in the hospital laboratory after
centrifugation at 3000 rpm for 10 mins. Detailed informa-
tion about demographic characteristics and blood sample
collection were previously described.20,22
The participants were then classified into the hyperten-
sion group [mean systolic blood pressure (SBP) ≥140
mmHg or mean diastolic blood pressure (DBP) ≥90
mmHg] or the normal blood pressure group (mean SBP
<120 mmHg and mean DBP <80 mmHg).25 Diagnosis of
type 2 diabetes was made by physicians according to the
1999 WHO Criteria [Fasting plasma glucose (FPG) greater
than or equal to 7.0 mmol/L].26 According to the guideline
for the prevention and control of dyslipidemia of adults in
China, the participants were grouped into dyslipidemia
with total cholesterol (TC) ≥6.2 mmol/L, or triglycerides
(TG) ≥2.3 mmol/L, or high-density lipoprotein cholesterol
(HDLC) <1.0 mmol/L, or low-density lipoprotein choles-
terol (LDLC) ≥4.1 mmol/L.20
IgG N-Glycans Analysis
IgG N-glycans were detected by the method of hydrophilic
interaction chromatography (HILIC)-ultra-performance liquid
chromatography (UPLC), which was reported in the previous
study.27 In brief, IgG was isolated using protein G monolithic
plates, and then IgG N-glycans were released, labelled and
purified, and finally IgGN-glycans were analyzed by 24 initial
glycan peaks (GPs). An additional 54 derived traits were
calculated by the remaining 24 directly measured glycans,
which were described in the published papers.27
Statistical Analysis
Continuous variables underlying normal distribution were
represented as themean± standard deviation (SD); otherwise,
medians (P25- P75) were used. The differences of continuous
Figure 1 The flow chart of study populations.
Dovepress Liu et al
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variables among the groups were tested by one-way ANOVA
or the Kruskal–Wallis tests. Categorical variables were repre-
sented as n (proportion), and the differences among the
groups were tested by chi-square tests. The association
between the two variables was performed using Pearson or
Spearmen’s rank correlation. The description of IgG glycans
was based on non-parametric methods because deviations
from normal distribution were observed. The Holm method
was applied to correct the multiple comparisons.
Analyses of associations between disease status and
glycan traits were performed using a logistic regression
model with age, sex, diabetes, hypertension and dyslipide-
mia included as additional covariates. Prior to correlation
and regression analysis, the z-score of normalized trans-
formations for IgG N-glycans was applied to add the
consistent comparability among IgG N-glycans.
To explore the association of FPG, SBP, DBP, TC, TG,
HDLC and LDLC on IgG N-glycans in the NWCA group,
canonical correlation analysis (CCA) was performed,
which determined the linear combination of variables
derived from two sets of the glycan structures (x) and
the indicators including FBG, SBP, DBP, TC, TG, HDLC
and LDLC (y). The identified variables with statistically
significant impact on the canonical variables were judged
by the canonical loadings. Generally, the absolute values
greater than 0.30 are used to define significant loadings.
Clustering analysis was performed on the difference
between IgG N-glycans in participants with NWCA to
identify the subgroups with the similarity in patterns of
glycan changes with the “clustergram” function (Matlab,
Mathworks USA) with “average linkage” option and “cor-
relation” distance both for rows (corresponding to each
glycans) and columns (average levels of glycans for each
group) defined as one Pearson’s correlation coefficient.
In addition, we combined the present study and the
European and West Australian study to explore the asso-
ciation of IgG N-glycans with BMI and WHR; the result
was to be expressed as correlation coefficient with 95% CI
and was analyzed using by the R package “metacor”.
Data analysis was performed using SPSS Statistics ver-
sion 24.0 for Windows (IBM Corp., Armonk, NY, USA), R
3.2.4 and SAS software version 9.4 (SAS Institute, Chicago,
IL, USA). All reported P values were two-sided, and P< 0.05
was considered statistically significant.
Results
Participant Characteristics
Finally, 1196 participants who had a complete dataset of
blood measurements and IgG N-glycan traits were
included in the further analysis. The basic characteristics
of all participants in four different obesity and central
adiposity groups (Table 1) were described. The detailed
information of the three studies is shown in the supple-
mental content (Table S1). In total, 9 clinical traits were
significantly different among the four groups (P<0.05/6).
Of note, the median (P25–P75) of age in the NWCA sub-
jects was 55 (49–63) years, which was higher than that in
Table 1 Characteristics Of Participants In Different Four Different Obesity And Central Adiposity Groups
Variables NW (n=545) ONCA (n=48) NWCA (n=427) OCA (n=176) P
Age 48 (43–53) 48.5 (44.5–54.5) 55 (49–63) 53 (47–60) <0.0001
BMI 23.55 (21.93–25.22) 28.96 (28.36–30.01) 25.53 (24.04–26.64) 29.84 (28.74–31.87) <0.0001
SBP 120 (110–126) 120 (115–135) 125 (117–138) 130 (120–142) <0.0001
DBP 77 (70–80) 80 (70–85) 74 (67–81) 80 (70–87) 0.0007
FPG 5.16 (4.86–5.64) 5.54 (5.11–6.53) 6.42 (5.37–8.25) 6.94 (5.66–8.18) <0.0001
TC 4.87 (4.25–5.48) 4.75 (4.46–5.39) 4.58 (3.92–5.27) 4.65 (4.05–5.49) 0.0001
TG 1.02 (0.76–1.51) 1.57 (1.14–2.4) 1.34 (0.97–2.03) 1.59 (1.11–2.36) <0.0001
LDLC 2.68 (2.24–3.11) 2.70 (2.40–3.13) 2.68 (2.19–3.28) 2.85(2.33–3.52) 0.0501
WHR 0.81 (0.77–0.85) 0.84 (0.81–0.87) 0.93 (0.91–0.96) 0.95(0.92–0.99) <0.0001
HDLC 1.59 (1.35–1.82) 1.41 (1.19–1.62) 1.26 (1.06–1.5) 1.17 (1.03–1.41) <0.0001
Male, n (%) 220 (40.37) 18 (37.50) 332 (77.75) 138 (78.41) <0.0001
Hypertension, n (%) 81 (14.86) 17 (35.42) 114 (26.70) 70 (39.77) <0.0001
Diabetes, n (%) 39 (7.16) 9 (18.75) 175 (40.98) 83 (47.16) <0.0001
Dyslipidemia, n (%) 103 (18.90) 18 (37.50) 152 (35.6) 82 (46.59) <0.0001
Notes: Data are shown as median (P25-P75) and n (proportion). P<0.05 indicated significance.
Abbreviations: BMI, body mass index; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose. NW, normal BMI with normal WHR; ONCA, obesity with
normal WHR; NWCA, normal BMI with central adiposity; OCO, obesity with central adiposity.
Liu et al Dovepress
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the other three groups. The proportion of males (77.75%)
in the NWCA group was higher than females (22.25%).
The prevalence of hypertension in the ONCA group was
higher than it in the NWCA group, whereas higher pre-
valence of diabetes was found in the NWCA group
(P<0.017). As shown in Figure S1, more than half of
1196 participants were classified as having obesity and
central adiposity. The prevalence of NWCA was 36%
with 95% CI (33–38%).
Associations Of IgG N-Glycans With
NWCA, ONCA And OCA
We performed the associations of IgG N-glycans with
obesity and central adiposity patients taking into consid-
eration adjusting for the effects of gender, age, diabetes,
hypertension and dyslipidemia. The association of signifi-
cant normalized IgG N-glycans with central adiposity was
not exactly the same as those with obesity (Figure 2).
Twelve normalized IgG N-glycans (GP4, GP5, GP7,
GP10, GP11, GP13, GP15, GP16, GP17, GP23 and
GP24) linking to central adiposity, which was more than
three normalized IgG N-glycans (GP1, GP7 and GP13)
connected with obesity, delineated the most remarkable
effect of glycans in the progression of central adiposity.
Statistically significant differences in IgG N-glycans
among four groups were observed after correction for
multiple comparisons (Figure 3). In total, 17 out of 24
initial IgG N-glycans were significantly different among
the four groups (NW, ONCA, NWCA and OCA) (P<0.05/
6*78=0.0001). Compared to NW population, 13 and 7
normalized IgG N-glycans found significant associations
with NWCA and OCA after adjusting for the effects of
gender, age, diabetes, hypertension and dyslipidemia
(Table S2), while no significant association was found in
ONCA. Compared to NW and ONCA, IgG N-glycans in
OCA population were always changing in company with
those in NWCA population implying that the progression
of central adiposity might be taken part in IgG glycosyla-
tion, which inspired us to further explore the connections
between glycans and central adiposity.
The profile of statistically significant correlations of IgG
N-glycans and NWCA and OCAwas not absolutely consis-
tent, but GP5, GP7, GP10, GP11, GP13, GP15 GP23 were
found to be statistically significantly associated with NWCA
and OCA (Figure 4). Derived traits were calculated
Figure 2 The profile of statistically significant correlations of IgG N-glycans with central adiposity (A) and obesity (B) after adjusting for the effects of gender, age, diabetes,
hypertension and dyslipidemia.
Dovepress Liu et al
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Figure 3 Differences of IgG N-glycans among NW, ONCA, NWCA and OCA in the whole populations. Data are shown as box and whiskers plots. Median was represented
by lines inside the boxes represented by the 25th to 75th percentiles. The whiskers appearing denoted the lowest and highest values. (P<0.05/6*78=0.0001 indicated
significant after multiple comparisons).
Liu et al Dovepress
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representing common biologically meaningful features (sia-
lylation, galactosylation glycan branching and fucosylation).
In parallel, 33 derived traits representing sialylation, galacto-
sylation glycan branching and fucosylation were found to be
statistically significantly associated with NWCA and OCA.
The changes of IgG N-glycans and glycosylation in the
NWCA group were more than those in the ONCA group.
The detailed information is described in the supplemental
content (Tables S3 and S4).
In the gross, changes in glycan expression correlated with
NWCA activity cannot be too worthy to investigate. GP4,
GP19, GP23 and GP24 were positively associated NWCA,
whereas GP5, GP7, GP10, GP11, GP13, GP15, GP17, GP18
and GP20 had negative relations with NWCA after adjusting
for age, sex, hypertension, diabetes and dyslipidemia. For the
derived glycans, IgG glycans showed lower level of galacto-
sylation (G1n and G2n) and higher level of agalactosylation
(G0n) for NWCApatients compared to the controls.While, the
level of bisecting N-acetylglucosamine (GlcNAc) (FBStotal/
FStotal, FBS1/FS1, FBS1/(FS1+ FBS1), FBS2/FS2 and
FBS2/(FS2+ FBS2)) and fucosylation (Fntotal and Fn) in the
NWCA patients was significantly higher than those in the
control group. In addition, the high level of FBGS/(FBG
+FBGS), FBGS/(FB+FBG+FBGS), FG2S2/(FG2+FG2S1
+FG2S2), FBG2S1/(FBG2+FBG2S1+FBG2S2) and FBG2
S2/(FBG2+FBG2S1+FBG2S2) increased the risk of NWCA,
while the low level of FtotalS1/FtotalS2 and FS1/FS2 increased
the risk of NWCA.
The IgG N-Glycans Patterns In The
NWCA Populations
In NWCA populations, seven pairs of canonical variables
in CCAwere shown, with canonical correlations of 0.6690
Figure 4 The profile of statistically significant correlations of IgG N-glycans with NWCA (A) and OCA (B) after adjusting for age, sex, hypertension, diabetes and
dyslipidemia.
Dovepress Liu et al
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(F= 2.56, P< 0.001), 0.3728 (F= 1.23, P=0.0418), 0.2877
(F= 0.97, P= 0.5714), 0.2654 (F= 0.85, P= 0.8370), 0.2349
(F= 0.68, P= 0.9684), 0.1489 (F= 0.47, P=0.9974) and
0.1465 (F= 0.49, P= 0.9621) for each successive pair by
the CCA. The first and the second canonical groups were
statistically significant, which demonstrated that IgG gly-
can traits were significantly linked to the clinical variables.
As shown in Figure 5, 10 initial IgG glycan traits (GP4,
GP5, GP7, GP8, GP13, GP15 and GP20) had the tendency
to be significantly related to FPG, SBP, DBP, TC, TG,
LDLC and HDLC levels in the first canonical group.
In addition, aiming to identify individuals with similar
patterns of changes, we have applied a bi-clustering algo-
rithm, which at the same time clusters changes in indivi-
dual glycans and group participants of NWCA according
to the similarity in patterns of glycan changes. As shown
in Figure 6, 2 subgroups including NWCA without any of
diabetes, hypertension and dyslipidemia and NWCA with
more than one of three disease outcomes were identified
using different IgG glycosylation patterns.
Discussion
The prevalence of the obesity and central adiposity are
rising worldwide. Our finding showed that 18.7% of sub-
jects were affected by obesity, 50.4% were affected by
central adiposity, more than half of the included participants
were classified as having obesity or central adiposity. In
addition, the prevalence rates of NWCA were 36.0%.
According to the data from the National Health and
Nutrition Examination Survey in the US,8,28 34.6% of sub-
jects were overweight, 25.1% were affected by obesity,
70.2% were affected by central adiposity and the prevalence
rates of NWCA were 11.7%. The cross-sectional studies
showed that the prevalence rates of NWCA were 36.9%
and 15.4% in South Africa and Thai, respectively.9,29 It may
be due to the different definition of obesity and central
adiposity that the reported prevalence rate of NWCA is
very different. However, NWCA is gradually developing
as a major health problem worldwide, and identification of
the underlying mechanism might translate new knowledge
into the prevention and treatment of central adiposity.
Combining the present study and previous studies,18,19
we found that BMI and WHR were positively associated
with GP4, GP6, and negatively associated with GP7,
GP12-15, GP17-18 and GP20 (Table 2). In our present
study, high level of GP23 and low level of GP5, GP7,
GP10, GP11, GP13 and GP15 increased the risk of NWCA
and OCA. In addition, lower galactosylation and bisecting
GlcNAc and higher fucosylation increased the risk of
NWCA. Consistent with previous studies,13,22,30 the
changes of lower galactosylation and bisecting GlcNAc
and higher fucosylation are involved in an imbalance of
the inflammatory response that increases the risk of dis-
eases. In addition, considering that accumulating evidence
indicates the changes in IgG glycosylation mechanism
could be a part of the molecular mechanism leading to
the promotion of inflammation,13,30 the changes of IgG
N-glycans and N-glycosylation in obesity and central adip-
osity may be one of the molecular mechanisms of inflam-
mation in NWCA.
The inflammatory role of IgG N-glycosylation in obe-
sity and central adiposity could be associated with chronic
inflammation as one of the characteristics of obesity and
central adiposity. Central adiposity involves impairment of
immune response affecting both innate and adaptive
immunity, and adipose tissue can produce and secrete
inflammatory molecules like tumor necrosis factor-α
(TNF-α) and interleukin-1 receptor-associated kinase
(IRAK)-1.16,17 Alternative IgG N-glycosylation plays a
crucial role in activation of complement by regulating
antibody-dependent cellular cytotoxicity (ADCC) and
complement-dependent cytotoxicity (CDC), thus acting
as a switch between pro- and anti-inflammatory IgG
functionality.14,15 Inflammatory disorders lead to several
signaling transduction pathways activation, inflammatory
cytokine chemokine production and cell migration, which
in turn cause metabolic dysfunction.31,32 Although the
causal relationship of central adiposity with inflammation
and IgG N-glycosylation is unknown, the changes in IgG
N-glycans observed in our study might also reflect the
chronic inflammatory processes in obesity and central
adiposity. Inflammation has emerged as one of the key
factors regulating obesity and central adiposity triggering
metabolic syndrome and other related disorders.33,34 There
are shared genes that have been associated with both IgG
glycosylation and obesity and central obesity (FUT8 and
IL6ST), and an established association between comple-
ment activation and obesity and central obesity; it is sug-
gested that pro-inflammatory IgG might be a contributor to
the disease pathophysiology in this disease.35
Furthermore, the changes of IgG N-glycans and
N-glycosylation in central adiposity were more than those
in obesity, which performed the stronger immune response in
central obesity. In addition, we found that that correlations of
IgG N-glycans with WHR were stronger than those with
BMI combining previous studies and the present study.
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Figure 5 Canonical structures of the normalized IgG N-glycan patterns and FPG, SBP, DBP, TC, TG, HDLC and LDLC in the first canonical set in the NWCA population.
The absolute value of canonical loadings greater than 0.30 was significant loadings. All of the variables are sorted by the absolute value of their canonical loadings. The
positive relationships are represented in black boxes, while negative relationships are shown in red boxes.
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Compared to NWand ONCA, IgG N-glycans in OCA popu-
lation were always changing in company with those in
NWCA population implying that the progression of central
adiposity might take part in IgG N-glycosylation. The mole-
cular mechanism of IgG N-glycosylation may explain that
central adiposity makes a greater contribution to the risk of
diseases than general obesity.8,9 The changes of IgG
N-glycans and N-glycosylation in NWCA were more than
those in OCA, indicating that IgGN-glycosylation performed
more effect on NWCA. Therefore, we continued to explore
the IgG N-glycans patterns in the NWCA populations. In
NWCA populations, we found that IgG N-glycans were
associated with the three disease outcomes including dia-
betes, hypertension and dyslipidemia, which would be
Figure 6 Clustering analysis on the difference between normalized IgG N-glycan patterns in the NWCA population. (A) Represented the changes in glycosylation among
four participant groups with all three diseases (hypertension and diabetes and dyslipidemia), two of these diseases, one of these diseases and none, respectively. (B)
Represented the changes in glycosylation among eight participant groups with all three diseases (hypertension and diabetes and dyslipidemia), two of these diseases
(hypertension and diabetes, diabetes and dyslipidemia and hypertension and dyslipidemia), one of these diseases (hypertension, diabetes and dyslipidemia) and none,
respectively.
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related disorders reduced by NWCA. In addition, bi-cluster-
ing analysis participants of NWCA revealed the existence of
two subgroups of patients with distinct patterns of IgG gly-
cosylation changes, which suggested us that NWCA as a
basic metabolic disorder with different IgG glycosylation
patterns which presented different inflammatory reaction
might reduce the different other related disease outcomes.
In our present study, there are several common limita-
tions and insufficiencies. First, the differential glycosyla-
tion described above may provide exciting insights into
pathogenesis of NWCA. However, causation is difficult to
infer in the observational data and the observed changes
may be a consequence rather than causes of the disease.
The distribution of four different obesity and central adip-
osity groups in our multi-center cross-sectional study was
uneven, which might lead to the evaluation bias. In addi-
tion, the study protocol should be registered previously to
ensure its feasibility. Furthermore, we only use WHR to
define central adiposity, which may induce evaluation bias.
Although the inflammatory role of IgG N-glycosylation
was performed in diseases, we should investigate other
inflammatory biomarkers to corroborate the inflammatory
status of obesity and central adiposity. Therefore, further
cohort studies with more comprehensive study design are
needed to provide a more definite explanation about the
role of IgG glycosylation in the association between
NWCA and its related disorders.
Conclusion
In summary, central adiposity was involved in more
changes of IgG N-glycosylation, representing a stronger
inflammation status than obesity, which might make a
greater contribution to the risk of related disorders.
NWCA was associated with an increased pro-inflamma-
tory of IgG N-glycosylation, which was accompanied by
the development of central adiposity and other related
disorders.
Data Sharing Statements
We do not intend to share any further data at present.
Table 2 IgG N-Glycans Associated With BMI And WHR
GPs BMI WHR
r (95% CI)# P r (95% CI) & P
GP1 −0.042 (−0.016–0.067) 0.0008 0.059 (0.011–0.103) 0.007
GP2 −0.009 (−0.035–0.017) 0.239 0.066 (0.021–0.112) 0.002
GP3 / / 0.010 (−0.0036–0.056) 0.332
GP4 0.090(0.064–0.116) <0.001 0.148 (0.103–0.193) <0.001
GP5 −0.019 (−0.045–0.007) 0.073 −0.176 (−0.132–0.220) <0.001
GP6 0.049 (0.023–0.075) 0.0001 0.092 (0.046–0.137) <0.001
GP7 −0.068 (−0.043–0.094) <0.001 −0.160 (−0.115–0.205) <0.001
GP8 0.013 (−0.027–0.025) 0.462 −0.084 (−0.039–0.129) <0.001
GP9 0.057 (0.031–0.083) <0.001 0.037 (−0.009–0.082) 0.058
GP10 0.009 (−0.017–0.035) 0.243 −0.086 (−0.040–0.131) 0.0001
GP11 0.053 (0.027–0.079) <0.001 −0.028 (−0.073–0.018) 0.119
GP12 −0.087 (−0.061–0.113) <0.001 −0.091 (−0.046–0.137) <0.001
GP13 −0.079 (−0.053–0.105) <0.001 −0.194 (0.150–0.238) <0.001
GP14 −0.100 (−0.074–0.126) <0.001 −0.105 (−0.060–0.150) <0.001
GP15 −0.081 (−0.055–0.107) <0.001 −0.155 (−0.110–0.199) <0.001
GP16 0.033 (0.007–0.059) 0.006 0.008 (−0.038–0.023) 0.363
GP17 −0.077 (−0.051–0.103) <0.001 −0.097 (−0.052–0.143) <0.001
GP18 −0.080 (−0.054–0.106) <0.001 −0.089 (−0.043–0.134) <0.001
GP19 −0.017 (−0.043–0.008) 0.094 0.004 (−0.042–0.050) 0.427
GP20 −0.055 (−0.028–0.081) <0.001 −0.182 (−0.138–0.227) <0.001
GP21 0.004 (−0.022–0.030) 0.389 −0.005 (−0.051–0.041) 0.412
GP22 −0.042 (−0.016–0.068) 0.0008 0.039 (−0.006–0.085) 0.046
GP23 −0.012 (−0.038–0.014) 0.173 0.056 (0.011–0.102) 0.008
GP24 −0.016 (−0.042–0.010) 0.113 0.058 (0.012–0.103) 0.007
Notes: #The result was combined with the data of 5689 individuals. &The result was combined with the data of 1833 individuals. /The association remains unclear.
Abbreviations: GP, glycan peak; BMI, body mass index; WHR, waist-to-hip ratio.
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